Vysali Pharmaceuticals Ltd - Company Profile

It is a pharma public limited company based in Ernakulam, Kerala, India, established in 1979.
1979 Ernakulam, Kerala, India Under Liquidation
Last Updated:
Access Report
About Vysali Pharmaceuticals Ltd

Vysali Pharmaceuticals Ltd, a under liquidation public limited company, was established on 29 October 1979 in Ernakulam, Kerala, India. Engaging in drug formulation & development within the manufacturing sector, it holds CIN: U24231KL1979PLC003112. Registered under ROC Roc Ernakulam. it is unlisted. It has an authorized capital of ₹10.00 Cr and a paid-up capital of ₹5.43 Cr.

It upholds a compliant status. Its leadership includes Kizhakkekara Kuriakose Jose (Irp/Rp/Liquidator), Valath Subramanian Sheelavelappan (Additional Director), Savithri Krishnan (Whole-Time Director). Past directors included Francis Mathew, Jadhavedhan Namboodiri Ashtathu Manakkal. It holds ₹30.26 Cr open charges and ₹19.46 Cr settled loans. Its latest AGM occurred on 26 November 2022, with the balance sheet filed on 31 March 2022. It is based at Ix/639 Vysali Road, Edathala P O, Ernakulam, Kerala, 683561.

Company Details
  • Email
    **********
  • Telephone

    +91-XXXXXXXXXX

  • Website
    **********
  • Social Media
    **********
  • Apps
    **********

Company Details

  • CIN/LLPIN

    U24231KL1979PLC003112

  • Registration Number

    003112

  • Incorporation Date

    29 October 1979

  • Authorized Capital

    ₹10.00 Cr

  • Paid-Up Capital

    ₹5.43 Cr

  • ROC Code

    Roc Ernakulam

  • Listing Status

    Unlisted

  • Company Status

    Under Liquidation

Key Metrics
  • Authorised Capital ₹ 10.00 Cr
  • Paid Up Capital ₹ 5.43 Cr
  • Company Age 46 Year, 4 Months
  • Last Filing with ROC 31 Mar 2022
  • Open Charges ₹ 30.26 Cr
  • Satisfied Charges ₹ 19.46 Cr
  • Revenue Growth **** -38.63%
  • Profit Growth **** 25.91%
  • Ebitda **** 10.32%
  • Net Worth -8.98%
  • Total Assets -3.13%
Company report

Vysali Pharmaceuticals Ltd

Company Report FY 2025-2026

Comprehensive Company Insights

Explore comprehensive insights into Vysali Pharmaceuticals Ltd — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.

Access Report
Who are the key members and board of directors at Vysali Pharmaceuticals Ltd?
Current Directors
Name Designation Appointment Date Status
Kizhakkekara Kuriakose Jose Irp/Rp/Liquidator 26 Feb 2024 Current
Valath Subramanian Sheelavelappan Additional Director 27 Sep 2019 Current
Savithri Krishnan Whole-Time Director 29 Oct 1979 Current
Alathur Damodaran Krishnan Managing Director 29 Oct 1979 Current
Past Directors
Name Designation Cessation Status
Pramod Abcsdd Irp/Rp/Liquidator 26 Feb 2024 Past
Pramod Abcsdd Whole-Time Director 27 Sep 2019 Past

Discover detailed profiles of directors and KMP - Unlock leadership insights today!

Financial Performance of Vysali Pharmaceuticals.

Vysali Pharmaceuticals Ltd, for the financial year ended 2022, experienced significant reduction in revenue, with a 38.63% decrease. The company also saw a substantial improvement in profitability, with a 25.91% increase in profit. The company's net worth dipped by a decrease of 8.98%.

Vysali Pharmaceuticals revenue growth over time
Vysali Pharmaceuticals profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors
Emtek
Feb, 2021 Amount Post-IPO - Grab Valuation

investors
Signite Partners
Jan, 2021 Amount Post-IPO - Grab Valuation

investors
Hana Financial Group , GGV Capital
Feb, 2021 Amount Post-IPO - Grab Valuation

investors
Signite Partners
  • Key Matrics
  • Balance Sheet
  • Profit and Loss
  • Cash Flow
  • Ratios
Metrics
(FY 2023) YOY Growth
(FY 2022) (FY 2021) (FY 2020) (FY 2019)
Total Revenue
********
 -38.63%
*******
*******
*******
*******
Revenue from Operations
*******
 -43.83%
*******
*******
*******
*******
Total Assets
*******
 -3.13%
*******
*******
*******
*******
Profit or Loss
*******
 25.91%
*******
*******
*******
*******
Net Worth
*******
 -8.98%
*******
*******
*******
*******
EBITDA
*******
 10.32%
*******
*******
*******
*******

Discover detailed financial data and - Unlock financial today!

What is the Ownership and Shareholding Structure of Vysali Pharmaceuticals?

In 2021, Vysali Pharmaceuticals had a promoter holding of 10.54% and a public holding of 89.45%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.

Shareholding Pattern (FY 2024)
shareholding
  • Promoters: 92.83%
  • Public: 4.10%
  • Others: 3.07%
Shareholding Pattern over the Year
FY (2024) FY (2023) FY (2022) FY (2021) FY (2020)
Promoters 92.83 94.62 94.55 94.55 94.55
Public 4.10 3.89 3.95 3.96 3.98
Others 3.07 1.49 1.50 1.49 1.47

Reveal ownership structures and financial performance - Get instant access now!

Charges (Loans)
Open Charges

₹302,600,000.00

Satisfied Charges

₹194,575,000.00

Charges Breakdown by Lending Institutions
  • Kerala State Industrial Development Corpn Ltd : 11.17 Cr
  • Kerala State Industrial Development Corporation Limited : 11.17 Cr
  • Kerala State Industrial Development Corportion Limited : 4.00 Cr
  • Others : 3.00 Cr
  • The Kerala State Industrial Development Corp. Ltd : 0.50 Cr
  • Others : 0.42 Cr
Latest Charge Details
Date Lender Amount Status
04 Sep 2019 Others ₹3.00 Cr Open
25 Oct 2007 Kerala State Industrial Development Corporation Limited ₹5.59 Cr Open
24 Oct 2007 Kerala State Industrial Development Corporation Limited ₹5.59 Cr Open
14 Jun 2007 Kerala State Industrial Development Corpn Ltd ₹5.59 Cr Open
13 Jun 2007 Kerala State Industrial Development Corpn Ltd ₹5.59 Cr Open

Explore comprehensive loan charge details -

How Many Employees Work at Vysali Pharmaceuticals?

Vysali Pharmaceuticals has a workforce of 0 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.

Employee Date Number of Employees
2020 78,000
2021 80,500
2022 83,200
2023 86,000
2024 89,500
2025 92,000
Deals i
Graph showing company valuation over time

Gain comprehensive insights into the Deals and Valuation data of Vysali Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Vysali Pharmaceuticals's trajectory.

Rating
Graph displaying rating trends over time

Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.

Alerts
Alert Indicator

Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.

Explore deal ratings and alerts - Get instant access now!

Latest Updates, News, and FAQs on Vysali Pharmaceuticals
Recent Activity within the Organization
  • Director Appointment

    The activity Kizhakkekara Kuriakose Jose was appointed as a IRP/RP/Liquidator was appointed as a IRP/RP/Liquidator on 26 Feb 2024 & has been associated with this company since 2 years 6 days . was completed.

  • Annual General Meeting

    Progress on Vysali Pharmaceuticals Ltd last Annual general meeting of members was held on 26 Nov 2022 as per latest MCA records. was documented.

  • Balance Sheet

    The activity Vysali Pharmaceuticals Ltd has filed its annual Financial statements for the year ended 31 Mar 2022 with Roc Ernakulam. was completed.

  • Director Appointment

    The activity Valath Subramanian Sheelavelappan was appointed as a Additional Director was appointed as a Additional Director on 27 Sep 2019 & has been associated with this company since 6 years 5 months . was completed.

  • Charges

    A charge with Others of Rs. 3.00 Cr registered on 04 Sep 2019 with Charge ID 100287909 was modified on 05 Sep 2019. was recorded as a recent event.

  • Charges

    Progress on A charge with Others amounted to Rs. 3.00 Cr with Charge ID 100287909 was registered on 04 Sep 2019. was documented.

Explore recent activity and updates - View Recent Activity

Frequently Asked Questions
What is the CIN of Vysali Pharmaceuticals Ltd?

The CIN of Vysali Pharmaceuticals Ltd is U24231KL1979PLC003112.

Where is Vysali Pharmaceuticals Ltd headquartered?

Vysali Pharmaceuticals Ltd is headquartered at Ix/639 Vysali Road, Edathala P O, Ernakulam, Kerala, 683561.

When was Vysali Pharmaceuticals Ltd incorporated?

Vysali Pharmaceuticals Ltd was incorporated on 29 October 1979.

Who are the current directors of Vysali Pharmaceuticals Ltd?

The current directors of Vysali Pharmaceuticals Ltd are

What is the primary industry of Vysali Pharmaceuticals Ltd?

The primary industry of Vysali Pharmaceuticals Ltd is Manufacturing.

Is Vysali Pharmaceuticals Ltd a listed company?

Vysali Pharmaceuticals Ltd is unlisted.

What is the capital structure of Vysali Pharmaceuticals Ltd?

The authorized capital of Vysali Pharmaceuticals Ltd is ₹10.00 Cr, and the paid-up capital is ₹5.43 Cr.

What is the compliance status of Vysali Pharmaceuticals Ltd?

The compliance status of Vysali Pharmaceuticals Ltd is Compliant.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available